nervous system disorder
Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million
Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder
Biogen and Sage Therapeutics Discontinue Development of SAGE-324 for Essential Tremor Following Mid-Stage Trial Failure
Biogen, Sage Therapeutics, SAGE-324, Essential Tremor, Mid-Stage Trial, Neurological Disorder, GABA Receptor Modulator, Clinical Development
J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure
Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders
Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering
Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.